10-Q: TScan Therapeutics Faces Nasdaq Delisting Risk, Cuts Jobs

TScan Therapeutics reported continued net losses and substantial doubt about its ability to continue as a going concern, while also receiving a Nasdaq delisting warning.

Summary

• TScan Therapeutics filed its Form 10-Q for the quarterly period ended September 30, 2026.
• The company reported a net loss of $33.1 million for the three months ended September 30, 2026, and $92.1 million for the nine months ended September 30, 2026.
• As of September 30, 2026, the company had $73.0 million in cash and cash equivalents.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations into Q4 2027.
• TScan received a notice from Nasdaq on August 27, 2026, stating its common stock failed to comply with the $1.00 minimum bid price rule, with an initial compliance period until February 23, 2027.
• The company implemented a workforce reduction of approximately 75% in September 2026, expected to yield cumulative cost savings of $55.0 million through the end of 2027.
• The company is prioritizing its in vivo solid tumor program, with plans to file an IND in Q3 2027 and dose the first patient in Q4 2027.
• Enrollment in the Phase 3 ALLOHA-2 study of TSC-101 has been stopped due to insufficient funding, though data collection continues.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to significant financial challenges, including a going concern warning and Nasdaq non-compliance, despite ongoing research efforts.

Positives

• The company is prioritizing its in vivo solid tumor program, with preclinical data expected in Q1 2027 and an IND filing planned for Q3 2027.
• Despite funding issues, data collection continues for the hematologic malignancies program, with updated data expected in Q4 2026 and Q2 2027.
• The company has $73.0 million in cash and cash equivalents as of September 30, 2026, which is expected to fund operations into the fourth quarter of 2027.

Negatives

• The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
• TScan Therapeutics is currently not in compliance with Nasdaq's continued listing requirements regarding the minimum bid price.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company implemented a significant workforce reduction of approximately 75% in September 2026.
• Enrollment in the Phase 3 ALLOHA-2 study has been stopped due to insufficient funding.
• Collaboration revenue decreased significantly, with the Amgen agreement terminating in November 2026.

Risks

• The company is not in compliance with Nasdaq's continued listing requirements and faces potential delisting.
• There is substantial doubt about the company's ability to continue as a going concern, requiring significant additional funding.
• The company has incurred significant losses and expects to continue incurring losses, with no revenue from product sales to date.
• The development of product candidates is complex, lengthy, and uncertain, with a high risk of failure.
• Global economic uncertainty and financial market volatility could make it more difficult to access financing.
• The terms of the loan agreement with Silicon Valley Bank place restrictions on operating and financial flexibility.
• The company may not be able to regain compliance with Nasdaq's minimum bid price rule, leading to delisting.
• The significant workforce reduction may disrupt operations and lead to loss of institutional knowledge.

Key Dates

Keywords

TCR-T therapy, biotechnology, clinical-stage, oncology, solid tumors, hematologic malignancies, Nasdaq compliance, going concern